Drugs & Targets START, Trialing collaborate to expand access to oncology clinical trials across Europe March 20, 2026Vol.52 No.11
Regulatory News Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again) March 13, 2026Vol.52 No.10By Claire Marie Porter
Regulatory News Prasad’s rule by fiat spilled into accelerated approvals in hematology and oncologyAtara Bio’s Cokey Nguyen: Normally, FDA wants to help us succeed. Now, “we’re getting new guidance at the last minute and it’s not helping.” March 13, 2026Vol.52 No.10By Jacquelyn Cobb
Guest Editorial As more people are surviving cancer, we must continue funding bold science March 13, 2026Vol.52 No.10By Karen E. Knudsen
Cancer Policy HHS postpones third USPSTF meeting in a row March 13, 2026Vol.52 No.10By Sara Willa Ernst
Cancer Policy FDA approves leucovorin for cerebral folate deficiency March 13, 2026Vol.52 No.10By Claire Marie Porter
In Brief Douglas Lowy and John Schiller to receive the 2026 Pezcoller Foundation-AACR award March 13, 2026Vol.52 No.10
In Brief Vivek Subbiah to lead Early Drug Development Program at Stanford Cancer Institute March 13, 2026Vol.52 No.10
In Brief Lonny Yarmus named head of the Division of Subspecialty Medicine at MSK March 13, 2026Vol.52 No.10
In Brief Mass General Brigham receives $50M gift for gene and cell therapy research March 13, 2026Vol.52 No.10
